Law Firms Urge Corcept Investors To Seek Lead Plaintiff Role In Securities Suit Over Relacorilant

Overview

• Investor-rights firms on Tuesday urged Corcept shareholders to seek lead-plaintiff status by April 21, 2026.
• A lead plaintiff represents the class and helps direct the litigation with chosen counsel.
• The lawsuit, pending in the U.S. District Court for the Northern District of California, claims Corcept touted relacorilant as near approval despite FDA warnings about weak evidence.
• Filings cite FDA feedback that the program, including the GRACE trial, did not convincingly show effectiveness for patients with hypercortisolism.
• The proposed class covers stock purchases from October 31, 2024, to December 30, 2025, and the court has not certified a class.